LL2-28 hindsight check: Ch 28 “In conclusion” (EEA 2013, report pp. 670–684)#

Strand A working file. Checked on 26 September 2026.

Method note. Web search was not available for this run because the session’s search budget was already used up. Every source below was therefore retrieved directly, from these places:

• EU law (EUR-Lex / Publications Office CELLAR): the full texts of regulations, directives, Commission reports and judgments.
• Peer-reviewed literature (Europe PMC, Crossref, Semantic Scholar, RePEc): abstracts, and full text where it is open access.
• PubMed E-utilities: publication counts, which I ran myself.
• Agency web pages: US EPA, CDC, WHO, Health Canada, USDA ERS, the European Commission press corner, the Ninth Circuit, and the White House.

A few items rest on secondary sources; these are flagged. Because I could not run open searches, any statement that I “found no” later work is weaker than it would otherwise be.

Overview#

Chapter 28 is the EEA’s unsigned synthesis of both Late lessons volumes. It makes empirical claims (about harm expansion, false positives, research imbalance and monopolies) and policy recommendations (on transparency, whistleblowing, compensation, tax shifting and accounting). Thirteen years on, the picture is uneven.

Diagnoses that have held up or strengthened

• Harm expansion for the agents the chapter names. Lead, asbestos, tobacco, ionising radiation and PCBs, plus air pollution, PFAS and (in the EU) BPA, have kept being found harmful at lower exposures. Regulators have repeatedly cut their exposure limits since 2013:
• EU asbestos limit reduced tenfold in 2023.
• WHO PM2.5 guideline halved in 2021.
• EFSA’s PFAS intake limit cut by two orders of magnitude between 2008 and 2020.
• EFSA’s BPA intake limit cut 20,000-fold in 2023.
• CDC and EPA now state that there is no safe level of lead.
• Persistent divergence between expert committees. BPA, glyphosate, titanium dioxide and aspartame show the same evidence being read differently by different committees, as the chapter said.
• Concentration in agri-biotech. Three mega-mergers in 2017–18 followed. The EU’s 2026 regulation on new genomic techniques now explicitly flags the risk that patents will concentrate the market.

Specific numbers that are fragile or misreported

• “4 of 88” false positives. No independent re-analysis has appeared. Chapter 2’s own caveats are missing from Ch 28. Later events cut both ways, since several of the chapter’s “emerging” concerns (brain tumours from mobile phones, safety of GM food) have moved towards no harm.
• The 1% hazard-research figure. It cannot be verified and conflicts with Ch 27’s 3%.
• “Half of all journal articles.” This comes from Grandjean et al. (2011) and misreads the paper. There, the top-20 substances account for about 12% of all chemical links, and “one-half” refers to the links within the top-100 substances. The paper does, however, confirm that the top ten substances are “all metals or metalloids”.

The GM health claim has weakened. The strongest claim, that some GM crops “present a threat to human health” (p. 674), is not supported by the post-2013 mainstream assessments:

• NASEM (2016)
• EU-funded G-TwYST (2019)
• The retraction of Séralini (2012) in November 2013

The ecological and agronomic concerns about the herbicides used with GM crops have partial support: herbicide-resistant weeds, the vacated dicamba registrations, and the EU’s exclusion of herbicide tolerance from its lighter regime for new genomic techniques. So does the concern about concentration.

Uptake of the recommendations has been lopsided

• Transparency: most uptake. The EU Transparency Regulation 2019/1381 applies from March 2021. The General Court ordered disclosure of glyphosate studies in 2019.
• Whistleblowing: formal uptake with a key gap. The EU Directive 2019/1937 protects reports of breaches of law, not scientific dissent about lawful but possibly hazardous products.
• Pre-funded no-fault compensation and liability bonds for novel technologies: essentially no uptake.
• Environmental tax shift: the opposite happened. Environmental taxes fell from 6.1% of EU tax and social-contribution revenue in 2021 to about 5.1–5.2% in 2024. Relative to 2014, their share of total taxation is down about 17%, while the labour-tax share has held steady.
• Natural-capital accounting: meaningful but partial progress. SEEA Ecosystem Accounting was adopted in 2021, and the EU made physical ecosystem accounts mandatory in 2024. Corporate sustainability reporting was cut back in 2026.

The “homo-illogical cycle” (vigilance fading after a crisis)

• Supported at the level of political direction. Japan dropped its pledge to reduce nuclear dependence (2025) and let reactor offline periods stop counting towards the 60-year limit (in force 2025). A 2025 US executive order calls the no-threshold radiation model “flawed” and imposes 18-month licensing deadlines.
• Not supported at the level of Japan’s post-Fukushima regulator. It refused Tsuruga-2 in 2024 over an active fault. It also suspended the Hamaoka 3 and 4 review after Chubu disclosed seismic-data problems in January 2026; an independent committee reported in September 2026 that the data had been manipulated since about 2012.

Weight to give the chapter

• Heavy weight for its mechanistic lessons: evidentiary asymmetry, harm expansion for confirmed hazards, opaque divergence between committees, concentration and lock-in, and the fading of institutional memory.
• Low weight for its headline statistics.
• Very low weight for its GM human-health sentence.
• Its governance agenda is best read as a scorecard, not a forecast. The parts that asked the least of incumbents (transparency) moved furthest. The parts that would have re-priced risk (tax shifts, pre-funded compensation) barely moved.

Verdict summary#

Claim 1: Only four of 88 alleged false positives were confirmed#

Original claim (p. 673). Acting on weaker evidence “will sometimes increase the number of false alarms — although the review of 88 cases of alleged false positives in Volume 2 … confirmed just four actual cases, suggesting that the risks are considerably less than sometimes claimed.” The chapter then argues that, where harm is irreversible, policy should tip “towards avoiding harm, even at the cost of more false alarms” (p. 673).

What Ch 28 leaves out. Chapter 2 (Hansen and Tickner) qualified the 88-case review in three ways:

• The classification into categories was partly subjective.
• About a third of the cases were ones where “the jury is still out”.
• The case list was drawn from critics’ lists of alleged over-regulation.

Ch 28 repeats the headline number without these qualifications. The case set was also contested before 2013: Cox (2007, Risk Analysis) argued that treating “uncertain” cases as not-false-positives biases the count, and Hansen, Krayer von Krauss and Tickner replied (Cox 2007; Hansen et al. 2007 response).

Subsequent developments

1. No systematic re-analysis found. I found no post-2013 study that re-scored the 88 cases or repeated the exercise on a fresh sample. The debate moved to case-by-case disputes and to reviews of how consistently the principle is applied: - Löfstedt (2014) called for a formal review of the EU’s use of the principle (Risk Management 16:137–163). - Garnett and Parsons (2017) reviewed 15 EU laws and judgments. They found the decision to invoke precaution “poorly defined” and that the Commission’s 2000 guidance “was not followed consistently in forming legislation”, although courts more consistently required “plausible evidence of potential hazard” (Risk Analysis 37(3), 2017; online 18 May 2016).

Neither supplies a new false-positive rate.

2. Several concerns the chapter itself flagged have moved towards “no harm”. - Mobile phones and brain tumours. The chapter cites these as an example of “no evidence of harm” being misread (p. 674) and lists them among emerging issues (p. 678).
   • MOBI-Kids, a case-control study in 14 countries of people aged 10–24, found “no evidence of a causal association between wireless phone use and brain tumours in young people” (Castaño-Vinyals et al., Environ Int, online 30 Dec 2021).
   • The systematic review commissioned by WHO found mobile-phone use “not associated with an increased risk of glioma” (mRR 1.01, 95% CI 0.89–1.13), meningioma or acoustic neuroma (Karipidis et al., Environ Int, 30 Aug 2024).
   • Safety of GM food. See Claim 5: NASEM (2016) and G-TwYST (2019).

If precautionary measures were taken on these concerns, later evidence would classify them as false positives, or at least as costly caution.

3. The EU now judges its own precautionary GMO regime ill-suited to some products. - The Commission’s 2021 study concluded that EU GMO law “is not fit for the purpose of regulating” plants from certain new genomic techniques. - Regulation (EU) 2026/1388, adopted 17 June 2026, now treats “category 1” edited plants like conventionally bred plants (Regulation (EU) 2026/1388, recital 8; EP procedure file).

Critics of precaution have tried to put a price on the regulatory delay: - Approval times for GE crops are longer in the EU than in the US (Smart, Blum and Wesseler, J Agric Econ 2017). - A real-options model estimated that the implied “perceived costs” of delaying Golden Rice in India were at least about US$199 million a year, which the authors associate with about 1.4 million life-years lost over a decade (Wesseler and Zilberman, Environ Dev Econ 2014). This is a model-based advocacy estimate, not an observed outcome.

4. Other “jury still out” style concerns have moved towards confirmed harm. Examples include the restriction of neonicotinoids to permanent greenhouses in 2018, BPA in the EU, and PFAS (Claim 3). The ledger therefore runs both ways.

Verdict: partly held up. The underlying point, that documented regulatory false positives are rarer than false negatives in the historical record, has not been overturned, and many alarms have since been confirmed. But the 4-of-88 statistic is fragile, its main caveats are dropped, and it has not been independently replicated. In the past decade, some high-profile precautionary positions have moved towards “no harm” (mobile phones and brain tumours, GM food safety), and the EU itself now says its GMO rules overreached for a class of products.

Implication for weight. Use the asymmetry argument (irreversibility makes false negatives costlier) as a sound conditional argument. Do not use “4 of 88” as a measured base rate. Any analytical lens built on this chapter should track false positives and their costs as carefully as false negatives. The chapter asks for this itself (p. 673) but does not do it.

Claim 2: Precaution stimulates innovation; monopolies hamper it#

Original claim. “There is now increasing evidence that precautionary measures do not stifle innovation, but can encourage it, in particular when supported by smart regulation or well-designed tax changes” (p. 670, citing Ambec et al. 2011 and Ashford and Hall 2011). “The timely use of the precautionary principle can often stimulate rather than hamper innovation, in part by promoting a diversity of technologies,” and “technological monopolies hamper innovation” (p. 673).

Subsequent developments

1. The Porter-hypothesis literature after 2013. It supports a weak version (regulation induces innovation) much better than a strong one (regulation improves competitiveness). - Ambec et al. was published in 2013. It found better support for the weak version than the strong one (REEP 7(1):2–22). - Dechezleprêtre and Sato’s review found:

   • “statistically significant adverse effects on trade, employment, plant location, and productivity in the short run” in pollution- and energy-intensive sectors, though these were “small relative to general trends”;
   • “evidence that environmental regulations induce innovation in clean technologies, but the resulting benefits do not appear to be large enough to outweigh the costs of regulations for the regulated entities” (REEP 11(2):183–206, July 2017).
   • Cohen and Tubb’s meta-analysis covered 103 studies and more than 2,000 estimates. They found “considerable heterogeneity”. A positive effect was “more likely at the state, region, or country level” than at firm level, “although in both cases the most likely scenario is statistical insignificance” (JAERE 5(2):371–399, 2018; abstract).
   • Well-identified causal evidence of induced innovation: the EU Emissions Trading System “increased low-carbon innovation among regulated firms by as much as 10%” without crowding out other patenting. This amounts to only about 1% of European low-carbon patenting (Calel and Dechezleprêtre, REStat 98(1), 2016).

2. Most of this literature is about environmental regulation in general, not precaution in particular. The digest already flags this conflation. The chapter’s own evidence (Ambec et al.) is about Porter-style regulation, not decisions taken under scientific uncertainty.

3. Evidence specific to precaution is mixed. - REACH, the EU’s precaution-based chemicals law.

   • For: the Commission’s 2018 review found that lighter requirements for new substances “have stimulated the development of new substances”. It found authorisation “is meeting its objectives to ensure proper control and foster substitution”. It estimated benefits “in the order of EUR 100 billion over 25–30 years”, against registration costs of EUR 2.3–2.6 billion (COM(2018) 116, 5 Mar 2018).
   • Against: the same review said “the authorisation requirements could be harming the competitiveness of EU companies”.
   • EU GMO law is the clearest counter-case. The EU legislature concluded that the regime was not fit for purpose for certain new genomic techniques, and then adopted a lighter regime (Claim 1), explicitly “to contribute to the innovation and sustainability goals” (Reg. 2026/1388).
   • Regrettable substitution (a Ch 28 theme, p. 676) continued within the same technological lineage. HFCs, the chemically similar substitute for CFCs that the chapter names, were phased down under the 2016 Kigali Amendment. Several of their fluorinated successors degrade to trifluoroacetic acid (TFA), which is now accumulating “irreversibly” in the environment (Arp et al., ES&T, 30 Oct 2024). Mandated substitution did stimulate innovation, but not necessarily safe innovation.

4. The policy climate turned against the “precaution is pro-innovation” framing. - Horizon Europe tells funded activities to “take advantage of and inspire innovation-friendly regulation, in line with the innovation principle” (Reg. (EU) 2021/695, recital 6, 28 Apr 2021). The regulation does not mention precaution. - The Commission’s Competitiveness Compass, drawing on the Draghi report, says European firms are “squeezed by high energy prices and a high regulatory burden”. It sets targets to cut reporting burden by 25% (35% for SMEs) (COM(2025) 30, 29 Jan 2025). - This is a policy judgement, not evidence. It shows that the chapter’s framing did not win the institutional argument.

5. “Monopolies hamper innovation” is partly vindicated by competition law, but the evidence is not one-sided. - In Dow/DuPont, the Commission found that the merger “would have reduced innovation” in a sector where “only five players are globally active throughout the entire research & development (R&D) process”. It required the divestment of “almost the entirety of DuPont’s global R&D organisation” (IP/17/772, 27 Mar 2017). - On Bayer/Monsanto, the Commission found that the deal as notified “would have significantly reduced competition on price and innovation” (IP/18/2282, 21 Mar 2018). - Against this, USDA’s Economic Research Service found that seed-sector consolidation was “accompanied by more private research and development (R&D) investment in crop agriculture, rapid diffusion of improved crop varieties to farmers, and higher farm productivity” (ERS EIB-256 summary, June 2023).

Verdict: partly held up. Regulation does induce innovation in targeted clean technologies, and competition authorities now treat loss of innovation competition as a real harm from concentration. But the stronger claim, that precautionary measures do not stifle innovation, is not borne out:

• The best meta-analytic evidence finds mostly null effects, with some short-run costs at firm level.
• The EU’s own GMO experience runs the other way.
• Induced substitutes can carry new hazards.

Implication for weight. Treat “precaution can steer innovation towards alternatives and diversity” as a plausible, conditional mechanism, strongest when price signals are well designed. Do not treat it as a general empirical law. The monopoly-and-lock-in lesson is more robust than the precaution-and-innovation lesson.

Claim 3: “Harm expansion” and no safe threshold#

Original claim (p. 672). For asbestos, tobacco, PCBs, lead and radiation, harm “turned out to be more diverse and widespread than anticipated”, and was “found to occur at lower and lower levels, such that, more often than not, no ‘safe’ threshold of exposure can be identified”. This “knowledge needs to be taken into account” for emerging issues. The chapter recommends “continuous, anticipatory reductions in exposures to emerging hazards” (p. 672). BPA is cited as a case where low doses may be more harmful than high ones (pp. 674, 677).

Subsequent developments: the named agents

• Lead
• A US cohort study (NHANES-III, followed up to 2011) linked rising blood lead from 1.0 to 6.7 µg/dL with higher cardiovascular mortality (HR 1.70). It estimated 412,000 attributable deaths a year in the US, describing low-level lead as “an important, but largely overlooked, risk factor” (Lanphear et al., Lancet Public Health, 12 Mar 2018).
• A global model estimated 5.5 million cardiovascular deaths and 765 million IQ points lost in 2019, with cardiovascular deaths “six times higher than the GBD 2019 estimate” (Larsen and Sánchez-Triana, Lancet Planet Health, 12 Sep 2023). This is modelling, and its dose-response assumptions are debated.
• Regulatory action:
  • CDC lowered its blood-lead reference value from 5 to 3.5 µg/dL on 28 Oct 2021 and states that “no safe BLL in children has been identified” (CDC).
  • EPA’s Lead and Copper Rule Improvements (8 Oct 2024) require lead pipes to be replaced within 10 years, on the premise that “there is no safe level of lead exposure” (EPA, page updated 29 Dec 2025).
• Asbestos. The EU cut its occupational limit tenfold, from 0.1 to 0.01 fibres/cm³, and to 0.002 fibres/cm³ from 21 Dec 2029 using electron microscopy. The directive states: “Because asbestos is a non-threshold carcinogen, it is not scientifically possible to identify a level below which exposure would not lead to adverse health effects” (Directive (EU) 2023/2668, 22 Nov 2023, recital 7).
• Tobacco. The 2014 US Surgeon General’s report added further diseases caused by smoking, including diabetes, liver and colorectal cancer, and age-related macular degeneration, and concluded that secondhand smoke causes stroke (The Health Consequences of Smoking — 50 Years of Progress, 2014). This is a textbook case of harm expansion.
• PCBs. IARC upgraded PCBs to Group 1, carcinogenic to humans, in 2013 (Lauby-Secretan et al., Lancet Oncol, 15 Mar 2013; IARC Monograph 107, 2015).
• Ionising radiation. INWORKS covers 309,932 nuclear workers. It found solid-cancer mortality rising 52% per Gy. Restricting the analysis to 0–100 mGy “approximately doubled the estimate”, suggesting “a steeper slope … in the low dose range”, and the estimate is larger than those “currently informing radiation protection” (Richardson et al., BMJ, 16 Aug 2023).

The institutional direction is now contested. US Executive Order 14300 calls models that “posit there is no safe threshold of radiation exposure” “flawed” (White House, 23 May 2025).

Subsequent developments: agents beyond the named five

• Air pollution
• WHO’s 2021 guidelines cut almost all guideline levels, citing “clear evidence of the damage air pollution inflicts on human health, at even lower concentrations than previously understood” (WHO, 22 Sep 2021).
• The recast EU directive adopts an annual PM2.5 limit of 10 µg/m³ by 2030, down from 25 µg/m³, with a view to aligning with WHO “at the latest by 2050” (Directive (EU) 2024/2881, 23 Oct 2024).
• US EPA lowered its annual PM2.5 standard from 12 to 9 µg/m³ on 7 Feb 2024 (EPA). It announced reconsideration on 12 Mar 2025 (EPA).
• PFAS

• EFSA’s guidance values fell sharply:

  • 2008: a PFOS TDI of 150 ng/kg bw per day (EFSA 2008).
  • 2018: TWIs of 13 ng/kg bw per week for PFOS and 6 for PFOA (EFSA 2018).
  • 2020: a group TWI of 4.4 ng/kg bw per week for four PFAS, based on immune effects in infants. EFSA noted that “parts of the European population exceed this TWI” (EFSA, 17 Sep 2020).

  For PFOS, the step from 2008 to 2020 is about two orders of magnitude. - IARC classed PFOA as Group 1 in 2023 (Zahm et al., Lancet Oncol). - EPA set PFOA and PFOS drinking-water limits of 4.0 ppt with a health goal of zero (10 Apr 2024). In May 2026 it proposed pushing PFOA/PFOS compliance to 2031 and rescinding the limits for four other PFAS and the hazard-index limit for their mixtures (EPA, updated 18 May 2026). - BPA: contested - EFSA’s 2023 re-evaluation set a TDI of 0.2 ng/kg bw per day, 20,000 times lower than 2015, based on immune (Th17) effects. It found exposure exceeded this “by two to three orders of magnitude” (EFSA Journal, 19 Apr 2023). The EU then banned BPA in food-contact materials (Reg. (EU) 2024/3190, 19 Dec 2024), with transitions running to 2026, 2028 and 2029. - BfR proposed a TDI 1,000 times higher (Kortenkamp et al., IJHEH 2024), and EMA formally disagreed (Zoeller et al., J Endocr Soc 2023). - The US FDA still says “BPA is safe at the current levels occurring in foods” (FDA page, current as of 20 Apr 2023). - Within CLARITY-BPA, academic studies reported effects “at the lowest dose tested” with “non-monotonic” responses (Heindel et al., Reprod Toxicol 2020), while the guideline core study underpinned FDA’s reassurance.

Test of the prediction that emerging hazards will follow the same path

• Food additive E171 (titanium dioxide). EFSA concluded it “can no longer be considered safe” because a genotoxicity “concern … could not be ruled out”, and the EU banned it (Reg. (EU) 2022/63, 14 Jan 2022). Health Canada found “no conclusive scientific evidence” of concern (Health Canada, updated 6 Apr 2023). This is harm expansion by precaution, not confirmed harm.
• Mobile phones and GM food have moved towards no harm (Claims 1 and 5). These are counter-cases the chapter’s framing does not anticipate.
• Selection effect. The five named agents were chosen because they turned out to be harmful. The pattern is a strong prior for confirmed hazards, not proof that every flagged hazard will expand.
• Thresholds are still set. For BPA and PFAS, regulators set ever-lower guidance values rather than declaring that no threshold exists. “No safe threshold” is formal doctrine only for lead, asbestos and genotoxic carcinogens, and it is a policy assumption for radiation.

Verdict: strengthened for the named agents and the other agents listed above. It is only a moderate general prior for new hazards.

Implication for weight. This is one of the chapter’s best-supported lessons. For hazards already confirmed, expect the scope to widen and the dose of concern to fall, and plan for exposure limits to be tightened repeatedly. For merely suspected hazards, the post-2013 record includes clear reversals, so the lesson supports keeping exposures low and paying for research, not a presumption that harm will be found.

Claim 4: Signs of technological monopoly in GMOs and nanotechnologies#

Original claim (p. 673). “Emerging technologies such as GMOs and nanotechnologies, where there are already signs of technological monopolies, driven by the high costs of research, development and production involved and the patent protections for developers” (citing Stirling 2007; van den Hove et al. 2012).

Subsequent developments: GM seeds and agrochemicals

1. Three mega-mergers were cleared with remedies. - Dow/DuPont, 27 Mar 2017 (IP/17/772). It was later split, with the agriculture business becoming Corteva. - ChemChina/Syngenta, 5 Apr 2017 (IP/17/882). - Bayer/Monsanto, 21 Mar 2018. The Commission said this created “the largest global integrated seed and pesticide player”, and reviewed “more than 2,000 different product markets” and “2.7 million internal documents” (IP/18/2282).
2. Measured concentration (USDA ERS). Over 2018–20, “two seed companies accounted for 72 percent of planted corn acres and 66 percent of planted soybean acres in the United States”. Stronger intellectual-property protection and biotech commercialisation were “major drivers” of consolidation, and mergers “played a significant role”. From 1990 to 2020, seed prices for crops grown mainly with GM traits rose 463%, against 270% for crop seed overall (EIB-256 summary, June 2023). ERS adds that high concentration “can often result from … innovations or the realization of scale economies”.
3. Lock-in through trait systems. In vacating the dicamba registrations, the Ninth Circuit held that EPA “entirely failed to acknowledge the substantial risk that the registrations would have anti-competitive economic effects in the soybean and cotton industries” (NFFC v. EPA, No. 19-70115, 3 Jun 2020). This refers to growers adopting tolerant seed defensively against drift. It is a vivid case of the “technological lock-in” dynamic the chapter describes.
4. The EU legislature has recognised the risk. The NGT Regulation requires: - disclosure of patent protection; - a code of conduct on licensing by 17 Jan 2028; - an expert group on NGT patenting; - a Commission assessment of effects on “competition in the plant-breeding sector, in particular from the perspective of small and medium-sized breeders, while considering the potential risks of market concentration” (Reg. (EU) 2026/1388, Arts 30–31).

Against this, some foundational trait patents have expired, which the chapter did not foresee.

Subsequent developments: nanotechnology

• No comparable consolidation emerged. As early as 2012, the Commission estimated the nanomaterials market at about 11 million tonnes and €20 billion, with “carbon black and amorphous silica” dominating (COM(2012) 572, 3 Oct 2012). These are long-established commodity materials with many producers.
• The patent literature describes a sprawling, cross-sectoral “garden” of thickets rather than a single controlling technology (Bowman, Sylvester and Marino 2017).
• I found no post-2013 evidence of a “technological monopoly” in nanotechnology in the chapter’s sense. Search limits make this finding weaker than usual.

Verdict: partly held up. For GM seeds and agrochemicals the concern was prescient: concentration increased sharply, and regulators now write patent and concentration safeguards into law. For nanotechnology it was not borne out; the technology diffused as an enabling toolkit across fragmented markets.

Implication for weight. The general mechanism holds: high R&D costs plus strong IP plus bundled product systems produce concentration and lock-in. Whether it operates depends on whether the technology is sold as an integrated proprietary system (seed and trait and herbicide) or as a diffuse enabling capability. The chapter’s pairing of GMOs with nanotechnology did not make that distinction.

Claim 5: GM crops threaten human health, species, ecosystems and food security#

Original claim (p. 674). “There is also evidence that some types of genetically modified crops (and the agrochemical substances used alongside them), which are released into the environment and the food chain, present a threat to human health, some species and ecosystems, and food security.” The sentence is uncited: it sits in a paragraph whose references (Barouki et al. 2012; EEA 2012; Kortenkamp et al. 2011) concern chemicals and endocrine disruptors. The digest notes that it goes beyond Ch 19.

Subsequent developments

1. Séralini et al. (2012) was retracted. The editor announced the retraction on 28 Nov 2013. According to secondary accounts, he called the results “inconclusive” while reporting “no evidence of fraud or intentional misrepresentation” (retraction notice, FCT, doi 10.1016/j.fct.2013.11.047; quotations via Wikipedia, “Séralini affair”, secondary). The study was republished without new peer-reviewed data in Environmental Sciences Europe on 24 Jun 2014 (doi 10.1186/s12302-014-0014-5).
2. The G-TwYST test. This EU-funded consortium was set up in response to the controversy. It ran two 90-day trials and a 2-year trial of NK603 maize, with and without Roundup, following OECD and EFSA guidance. It concluded “no adverse effects related to the feeding of the NK603 maize … for up to 2 years were observed” (Steinberg et al., Arch Toxicol, 12 Feb 2019).
3. NASEM (2016) found “no substantiated evidence that foods from GE crops were less safe than foods from non-GE crops”. It also found that: - Bt crops supported higher insect biodiversity than conventional crops sprayed with insecticide; - where glyphosate was relied on heavily, “some weeds evolved resistance and present a major agronomic problem”; - “damaging levels of resistance evolved in some target insects”; - yield gains were modest (Genetically Engineered Crops: Experiences and Prospects, 2016; summary).
4. No GMO environmental-damage incidents in the EU. The Commission’s 2016 report on the Environmental Liability Directive recorded “no incidents of environmental damage caused by GMOs … in the EU within the reporting period” of 2007–2013 (COM(2016) 204, 14 Apr 2016). Cultivation in the EU was very limited, so this is weak evidence either way.
5. Evidence on the companion herbicides is contested. - IARC classed glyphosate as “probably carcinogenic” (Group 2A) in March 2015. - ECHA’s Risk Assessment Committee concluded that glyphosate “does not meet the criteria to be classified as carcinogenic, mutagenic or toxic for reproduction”. The EU renewed its approval to 15 Dec 2033, while noting that “possible indirect effects” on biodiversity “could not be excluded” (Implementing Reg. (EU) 2023/2660, 28 Nov 2023, recitals 8 and 22). - For dicamba used over the top of tolerant crops, the Ninth Circuit found that EPA had “substantially understated” drift risks and vacated the registrations (3 Jun 2020, opinion). This is documented off-target harm to non-tolerant crops from a herbicide tied to a GM trait.
6. EU legislators acted on the agronomic concern. The NGT Regulation excludes herbicide tolerance from the lighter category-1 regime. It states that such traits “can lead to the development of weeds resistant to those herbicides or to the need to increase the quantity of herbicides applied … with the risk of a negative impact on human and animal health and the environment” (Reg. (EU) 2026/1388, recital 19).
7. Food security. I found no mainstream assessment identifying GM crops as a threat to food security. NASEM’s yield findings are modest, not negative.

Verdict: weakened. The human-health strand is contradicted by the post-2013 mainstream assessments, and its best-known support has been retracted. The food-security strand is unsupported. What survives is narrower and better stated as: herbicide-tolerance systems create agronomic and ecological problems (resistant weeds, drift damage, possible indirect effects on biodiversity), and their companion herbicides remain the subject of divergent hazard and risk assessments.

Implication for weight. This sentence should carry very little weight. It is a caution about using the chapter’s summary claims without checking them against the case chapters. It is also an example of the chapter departing from its own standards on citation and transparency.

Claim 6: About 1% of Framework Programme funding went on hazard research#

Original claim (p. 679). “In the period 2002–2013, about 1% of the total amount that the EU Framework Programmes … allocated to developing products from nanotechnologies, biotechnologies and ICT was spent researching their potential hazards.” Correcting the imbalance is recommended. Ch 27 gives “about 3% of EUR 28.5 billion” (p. 646).

Subsequent developments and checks

1. The denominator can be approximately reconstructed. FP7’s relevant themes were:

Source: Decision 1982/2006/EC, Annex II. Adding the corresponding FP6 (2002–06) priorities (FP6 decision 1513/2002/EC; its budget tables did not come through in the text I retrieved) plausibly takes the total close to Ch 27’s €28.5 billion. On that base, 1% is about €285 million and 3% about €855 million. 2. Known hazard-related lines. The Commission reported “more than EUR 200 million” for GMO biosafety research under the Framework Programmes, 2001–2010, across 50 projects and more than 400 research groups. Part of this went on co-existence and detection tools, not hazard research as such (EC, A decade of EU-funded GMO research (2001–2010), 2010, archived copy). Nanosafety and electromagnetic-field research would add to this, but I could not retrieve an authoritative total. A plausible total therefore lies between about 1% and 2% of the base. Neither the 1% nor the 3% figure can be confirmed, and the report gives no source for either. 3. After 2013 - Horizon 2020 and Horizon Europe continued to fund nanosafety as a cluster, since broadened to “safe and sustainable by design” chemicals and materials (NSC network; Commission Recommendation (EU) 2022/2510, 8 Dec 2022). - The EURION cluster (Horizon 2020, 2019–) put €50 million into test methods for endocrine disruptors (EURION). - PARC, the Partnership for the Assessment of Risks from Chemicals, launched on 11 May 2022. It has €400 million over seven years, half from the EU, and aims to “better anticipate emerging risks” (PARC). - These are real increases in hazard-oriented funding. But no official metric reports the hazard share of product-development funding, so whether “the imbalance” has been corrected cannot be measured. - Later reviews suggest that EU nanosafety projects generated a lot of data that was not published or poorly curated. For example, silver was “vastly over-represented” and carbon black under-represented relative to production volumes (Pomar-Portillo et al., NanoImpact 2021). How the hazard money was spent matters as well as how much there was.

Verdict: unclear. The direction of the claim (hazard research is a small fraction of development funding) is very likely right. The magnitude is unsourced, internally inconsistent across chapters, and unverifiable.

Implication for weight. Use the qualitative lesson that anticipatory hazard research is structurally underfunded compared with development. Do not quote “1%” (or “3%”) without a caveat. The post-2013 growth of dedicated hazard partnerships shows that the recommendation was partly acted on.

Claim 7: Research concentrates on well-known hazards and crowds out emerging ones#

Original claim (p. 675). Citing Grandjean et al. (2011): “The top ten substances studied are all metals such as copper, lead, zinc and cadmium. These established hazards account for approximately half of all the journal articles on impacts of chemical substances of the last ten years.” This “has crowded out research into other dangerous hazards … such as on endocrine-disrupting substances”.

Source check (not hindsight, but material). The full text of Grandjean et al. (2011, Environ Health 10:96; doi, PMC3229577) says:

• the top-10 substances “are all metals or metalloids” (confirmed);
• the top-20 substances “contributed 12% toward the total number of links”;
• the top-100 substances made up 24% of links, and “one-half of these links referred to the top-20 substances”.

“Approximately half of all the journal articles” therefore appears to misread “one-half of the top-100’s links”. The correct figure is about 12% of all chemical links, a strong Matthew effect but about a quarter of the size claimed. Grandjean et al. do not mention endocrine disruptors, so the crowding-out point is the chapter’s own inference.

Subsequent developments. I counted publications in PubMed myself, via E-utilities on 26 Sep 2026, using title and abstract searches. These counts are indicative only: they are not restricted to environmental journals, copper and cadmium include non-toxicological work, and 2025 counts may still rise slightly as indexing continues.

Institutional attention also shifted:

• The EU created new hazard classes for endocrine disruption and for persistent-mobile-toxic substances. The regulation states that “it has been proven that endocrine disruption can lead to certain disorders in humans” (Delegated Reg. (EU) 2023/707, 19 Dec 2022).
• EURION and PARC target these hazards directly (Claim 6).
• EFSA’s PFAS opinion drew on human epidemiology of immune effects (Claim 3).

Verdict: partly held up. The Matthew-effect mechanism is well supported by the cited paper, but the chapter overstated its size about fourfold. After 2013, attention shifted markedly towards PFAS, endocrine disruptors and new pollutants such as microplastics, which grew much faster than PubMed overall and than lead and mercury. Some of that shift came through the funding and regulatory channels the chapter recommended. Metals remain heavily studied in absolute terms.

Implication for weight. “Research attention is path-dependent” is a sound mechanism. The post-2013 record shows it can be overcome when regulators and funders create demand, often after a high-profile contamination case. Do not reuse the “half of all articles” figure.

Claim 8: Broader, more transparent risk assessment, and divergent committees#

Original claim (pp. 677–678).

• Risk assessments should be “broader-based, more inclusive, transparent and accountable”.
• Committees should explain their “choice of paradigms, assumptions, criteria for accepting evidence, weights … and how uncertainties were handled”.
• Funding sources should be made explicit.
• All submitted data should be made accessible, with EFSA’s January 2013 initiative noted.
• There is “significant divergence in the evaluations of the same, or very similar, scientific evidence by different risk assessment committees” (examples include BPA).

Subsequent developments

1. Transparency reform was adopted - Regulation (EU) 2019/1381 (20 Jun 2019, applying from 27 Mar 2021) provides for:

   • proactive public disclosure of studies submitted by industry;
   • public consultation on submitted studies;
   • notification of commissioned studies;
   • EU-funded “verification studies” where there are “serious controversies or conflicting results”.

   Its recitals cite the European Citizens’ Initiative on glyphosate as having “further confirmed concerns regarding transparency” (Reg. (EU) 2019/1381). - The General Court annulled EFSA’s refusal to disclose glyphosate toxicity studies, treating them as information relating to emissions into the environment (T-716/14 Tweedale v EFSA, 7 Mar 2019). - EFSA issued cross-cutting guidance on explaining reasoning (Weight of evidence, 3 Aug 2017; Uncertainty analysis, 24 Jan 2018). Its 2023 BPA opinion used a pre-registered protocol that had gone through public consultation. 2. Divergence persisted, and in places grew - BPA. EFSA’s TDI was opposed by BfR (a TDI 1,000 times higher) and by EMA, and FDA maintains its position of safety (Claim 3). One analysis traced the split between EFSA and BfR mainly to “the refusal by BfR to accept immunotoxic effects as the basis” for a guidance value, and to evaluation schemes that omit “entire streams of evidence” (Kortenkamp et al. 2024). This is the kind of explanation of divergence the chapter asked for, but it was supplied by outside scientists, not by the committees. - Glyphosate. IARC (Group 2A, 2015) against ECHA RAC and EFSA (not classifiable as carcinogenic; EU renewal 2023). - E171. EFSA against Health Canada (Claim 3). - Aspartame. IARC “possibly carcinogenic (Group 2B)”, while JECFA reaffirmed the ADI of 40 mg/kg bw. WHO issued a single communication explaining that hazard identification and risk assessment answer different questions (WHO, 14 Jul 2023). This is a partial example of the explanatory practice the chapter recommended.

Verdict: held up. The diagnosis that committees diverge over the same evidence, often for unexplained or value-laden reasons, has been repeatedly confirmed since 2013. The recommended direction of reform was substantially adopted in EU food-chain law. Institutional explanations of divergence remain the exception rather than the rule.

Implication for weight. Strong. Transparency of data and reasoning is the most institutionalised of the chapter’s recommendations. Note the pattern: reform came after a mass public mobilisation and litigation over a single high-profile substance, not from the general argument.

Claim 9: Protect early warners, and create pre-funded no-fault compensation and liability bonds#

Original claim.

• Early warners “should receive better protection via the extension of ‘whistle blowing’ and discrimination laws” (p. 676).
• “Prompt and anticipatory no-fault compensation schemes … could be set up and financed in advance of potential harm by the industries that are producing novel and large-scale technologies” (p. 679).
• Anticipatory liability bonds should be considered (pp. 679–680).
• Precedents are cited for nuclear accidents, oil spills and contamination by GM crops.

Subsequent developments: whistleblowing

• The EU Whistleblower Directive covers environmental protection, radiation protection and nuclear safety, food and feed safety, public health and consumer protection (Directive (EU) 2019/1937, 23 Oct 2019).
• The key limit: it protects reports of “breaches”, meaning acts that “are unlawful” or “defeat the object or the purpose” of EU rules. A scientist warning about an emerging hazard from a lawful, authorised product, the typical early warner in these cases, is not clearly covered.
• Implementation was slow. Only 3 Member States had transposed the directive fully by the December 2021 deadline. The Commission opened infringement proceedings against 24 in January 2022 and referred 6 to the Court of Justice in March 2023. A “large majority” of Member States extended national coverage beyond the directive’s scope (COM(2024) 269, 3 Jul 2024).
• The EU anti-SLAPP Directive protects people who take part in public debate on matters of public interest, explicitly including “researchers and academics” and environmental defenders, against abusive cross-border lawsuits. Transposition was due by 7 May 2026 (Directive (EU) 2024/1069, 11 Apr 2024). This addresses one of the forms of harassment listed on p. 676 (“legal or other threats”).

Subsequent developments: compensation and liability

• No new pre-funded no-fault scheme for a novel technology. I found none at EU level between 2013 and 2026.
• Environmental Liability Directive. The Commission’s 2016 evaluation found financial security voluntary and demand for it “low”, with “problems persist[ing] regarding … large-scale accidents and insolvency” (COM(2016) 204). Mandatory financial security was not introduced.
• Product Liability Directive (2024). The revised directive, for products placed on the market after 9 Dec 2026, extends the long-stop to 25 years where “the symptoms of a personal injury are … slow to emerge”. This partly addresses the justice lag of the latency cases. But it keeps the “development risk defence” (no liability where the state of scientific knowledge could not reveal the defect), leaving Member States free to derogate (Directive (EU) 2024/2853, 23 Oct 2024). That defence is structurally at odds with the chapter’s no-fault logic for novel technologies.
• Air quality. The recast directive gives individuals a right to compensation from authorities for health damage caused by intentional or negligent breaches of air-quality rules (Directive (EU) 2024/2881). This compensation is fault-based and paid by the state, not pre-funded by industry.
• Nuclear. The precedent regime was strengthened: the 2004 Protocol to the Paris Convention entered into force on 1 Jan 2022, raising minimum operator liability. This rests on a secondary source (Wikipedia summary); the NEA page was not retrievable.

Verdict: partly held up.

• Whistleblowing: partial uptake in form, but a scope that largely misses the chapter’s target group.
• Pre-funded no-fault compensation and bonds: essentially no uptake. Liability law moved incrementally (longer latency windows) while keeping the development-risk defence.

Implication for weight. The diagnosis is supported by continuing ex-post litigation over latent harms: justice lags harm, and early warners face retaliation. The remedy has not been tested in practice, so its claimed incentive effect, that pre-funded schemes prompt companies to do more hazard research first, remains conjecture. The digest also notes that Ch 24 is in tension with it. Treat it as a design proposal, not an evidence-based lesson.

Claim 10: The homo-illogical cycle, environmental tax shift and natural-capital accounting#

Original claim.

• After a hazardous event, “lessons are soon forgotten” and “willingness to invest in risk research, long-term monitoring etc. decreases sharply”. Chernobyl and Fukushima are “cases in point” (p. 680).
• Tax should shift from labour to pollution, with rates rising and falling as knowledge about harm grows or shrinks (p. 679).
• Firms and governments should extend accounting to human and natural capital (p. 679, citing the UN 2012 SEEA Central Framework).

Subsequent developments: nuclear vigilance after Fukushima

• Institutionalised learning, which runs against the cycle
• The EU amended its Nuclear Safety Directive after the Fukushima “stress tests”. It introduced EU-wide topical peer reviews every six years (Council Directive 2014/87/Euratom, 8 Jul 2014).
• Japan’s Nuclear Regulation Authority, created in 2012, has approved only 15 restarts. It refused Tsuruga-2 in November 2024 over an active fault.
• After Chubu Electric disclosed seismic-data problems (January 2026), the NRA suspended its review of Hamaoka 3 and 4. An independent committee reported in September 2026 that data submitted to the regulator had been “manipulated since around 2012”, and Chubu withdrew its applications (World Nuclear Association Japan profile, updated 22 Sep 2026; an industry-association source). This is a striking example of the chapter’s themes of evidence shaped by interests and of regulatory vigilance.
• Safety upgrades have been costly. One example is an estimated ¥570 billion for Onagawa 2 (same source).
• Political drift, consistent with the cycle
• In Japan, the 2023 GX legislation lets offline periods stop counting towards the 60-year lifetime (in force June 2025). The February 2025 Strategic Energy Plan dropped the post-Fukushima phrase “reducing nuclear dependency as much as possible”. Kashiwazaki-Kariwa 6 restarted in January 2026 (same source).
• In the US, EO 14300 imposes a deadline of no more than 18 months for final decisions on new reactor licences and calls the no-threshold radiation model “flawed” (23 May 2025).
• This drift is partly a response to climate and energy-security goals, not simply forgetting. The chapter’s framing does not distinguish deliberate re-weighting of risk from memory decay.

Subsequent developments: environmental tax shift

Eurostat (data extracted July 2026) reports:

• EU environmental taxes were €371.9 billion in 2024: 2.1% of GDP and 5.1% of revenue from taxes and social contributions (5.2% excluding imputed contributions), down from 6.1% in 2021.
• As a share of total taxation, environmental taxes were at index 83.2 in 2024 (2014 = 100), “a 16.8% decrease compared to 2014”. Labour taxes stayed “relatively stable”.
• Pollution and resource taxes, the kind the chapter proposes, are only 4.8% of environmental tax revenue (Eurostat, Environmental tax statistics).

The shift the chapter recommended did not happen; the environmental share moved the other way. Carbon pricing grew mainly through emissions trading, not through the evidence-indexed pollution taxes the chapter describes.

Subsequent developments: natural-capital accounting

• The UN Statistical Commission adopted SEEA Ecosystem Accounting in March 2021. Only chapters 1–7 (the framework and physical accounts) became the statistical standard (SEEA EA; Reg. (EU) 2024/3024, recital 4).
• The EU made ecosystem accounts a mandatory statistical module (first reference year 2023). Monetary valuation was deferred to feasibility studies due by 27 June 2026 (Reg. (EU) 2024/3024, 27 Nov 2024).
• The Kunming-Montreal Global Biodiversity Framework (Target 14, Dec 2022) calls for integrating biodiversity values into “national accounting” (CBD).
• On the corporate side, the EU cut back: mandatory sustainability reporting is now limited to undertakings with more than 1,000 employees and a net turnover above €450 million, and due-diligence thresholds were raised to 5,000 employees and €1.5 billion (Directive (EU) 2026/470, 24 Feb 2026).

Verdict: partly held up.

• The cycle diagnosis fits the political direction of nuclear policy in Japan and the US, but not the behaviour of independent regulators, where post-crisis institutions have held.
• The tax-shift recommendation was not adopted and moved backwards.
• Natural-capital accounting was adopted at national-statistics level, in physical rather than monetary form, and weakened at corporate level.

Implication for weight. “Vigilance decays unless it is institutionalised” is well supported; the post-2013 record suggests that independent institutions with legal mandates are what break the cycle. That is a more useful and more specific lesson than the chapter’s appeal to human creativity. The fiscal and accounting recommendations show that the proposals the chapter treats as most transformative, re-pricing and re-accounting, are the least politically durable, especially when cost-of-living and competitiveness pressures are high.

Additional notes relevant to this section’s legacy#

• Minamata memorial (p. 683). The Minamata Convention on Mercury, adopted in 2013 in Kumamoto, entered into force on 16 Aug 2017 (minamataconvention.org; the page could not be retrieved in this run, so this is well documented but unverified here). It is a post-2013 institutional outcome of the case Harada worked on.
• Neonicotinoids (p. 674, bees). EFSA’s assessments identified “high acute risks for bees”, and the EU limited imidacloprid, clothianidin and thiamethoxam to permanent greenhouses (Implementing Reg. (EU) 2018/783, 29 May 2018, with 2018/784 and 2018/785). This is a post-2013 vindication of an early warning the chapter highlights.
• Nanomaterial governance. A 2023 stock-take by authors including Ch 2’s Hansen found that more than 90% of the 2004 Royal Society and Commission recommendations on nanomaterials had since been met to a “high” or “medium” degree, while gaps remained in measurement, definitions and waste law (Nielsen et al., NanoImpact, 10 Oct 2023). This is evidence that anticipatory governance of an emerging technology can work incrementally, a counterpoint to the chapter’s pessimism.

Sources#

The date in each entry is the publication or decision date, or the page-update date where the page gave one. All were accessed on 26 Sep 2026 unless noted.

EU legislation, decisions and Commission documents (EUR-Lex; full texts retrieved via the Publications Office CELLAR service) - Council Directive 2014/87/Euratom (8 Jul 2014), amending the Nuclear Safety Directive. https://eur-lex.europa.eu/eli/dir/2014/87/oj - Decision 1982/2006/EC (18 Dec 2006), FP7 (Annex II budget breakdown). https://eur-lex.europa.eu/eli/dec/2006/1982/oj - Commission Implementing Regulation (EU) 2018/783 (29 May 2018), imidacloprid. https://eur-lex.europa.eu/eli/reg_impl/2018/783/oj - Regulation (EU) 2019/1381 (20 Jun 2019), transparency of EU risk assessment in the food chain. https://eur-lex.europa.eu/eli/reg/2019/1381/oj - Directive (EU) 2019/1937 (23 Oct 2019), protection of persons who report breaches of Union law. https://eur-lex.europa.eu/eli/dir/2019/1937/oj - Regulation (EU) 2021/695 (28 Apr 2021), Horizon Europe. https://eur-lex.europa.eu/eli/reg/2021/695/oj - Commission Regulation (EU) 2022/63 (14 Jan 2022), titanium dioxide (E 171). https://eur-lex.europa.eu/eli/reg/2022/63/oj - Commission Recommendation (EU) 2022/2510 (8 Dec 2022), safe and sustainable by design. https://eur-lex.europa.eu/eli/reco/2022/2510/oj - Commission Delegated Regulation (EU) 2023/707 (19 Dec 2022; OJ 31 Mar 2023), new CLP hazard classes (endocrine disruptors, PMT/vPvM). https://eur-lex.europa.eu/eli/reg_del/2023/707/oj - Directive (EU) 2023/2668 (22 Nov 2023), asbestos at work. https://eur-lex.europa.eu/eli/dir/2023/2668/oj - Commission Implementing Regulation (EU) 2023/2660 (28 Nov 2023), renewal of glyphosate. https://eur-lex.europa.eu/eli/reg_impl/2023/2660/oj - Directive (EU) 2024/1069 (11 Apr 2024), anti-SLAPP. https://eur-lex.europa.eu/eli/dir/2024/1069/oj - Directive (EU) 2024/2853 (23 Oct 2024), product liability. https://eur-lex.europa.eu/eli/dir/2024/2853/oj - Directive (EU) 2024/2881 (23 Oct 2024), ambient air quality (recast). https://eur-lex.europa.eu/eli/dir/2024/2881/oj - Regulation (EU) 2024/3024 (27 Nov 2024), environmental economic accounts: ecosystem accounts. https://eur-lex.europa.eu/eli/reg/2024/3024/oj - Commission Regulation (EU) 2024/3190 (19 Dec 2024), BPA and other bisphenols in food-contact materials. https://eur-lex.europa.eu/eli/reg/2024/3190/oj - Directive (EU) 2026/470 (24 Feb 2026), Omnibus I amendments to sustainability reporting and due diligence. https://eur-lex.europa.eu/eli/dir/2026/470/oj - Regulation (EU) 2026/1388 (17 Jun 2026; OJ 26 Jun 2026), plants obtained by certain new genomic techniques. https://eur-lex.europa.eu/eli/reg/2026/1388/oj - European Parliament Legislative Observatory, procedure 2023/0226(COD). https://oeil.secure.europarl.europa.eu/oeil/en/procedure-file?reference=2023/0226(COD) - COM(2012) 572 (3 Oct 2012), Second Regulatory Review on Nanomaterials. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52012DC0572 - COM(2016) 204 (14 Apr 2016), report under Art. 18(2) of the Environmental Liability Directive. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52016DC0204 - COM(2018) 116 (5 Mar 2018), General Report on the operation of REACH. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52018DC0116 - COM(2024) 269 (3 Jul 2024), implementation of the Whistleblower Directive. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52024DC0269 - COM(2025) 30 (29 Jan 2025), A Competitiveness Compass for the EU. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52025DC0030 - General Court, Case T-716/14 Tweedale v EFSA (7 Mar 2019). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62014TJ0716 - European Commission press releases: IP/17/772 Dow/DuPont (27 Mar 2017), https://ec.europa.eu/commission/presscorner/detail/en/IP_17_772; IP/17/882 ChemChina/Syngenta (5 Apr 2017), https://ec.europa.eu/commission/presscorner/detail/en/IP_17_882; IP/18/2282 Bayer/Monsanto (21 Mar 2018), https://ec.europa.eu/commission/presscorner/detail/en/IP_18_2282 - European Commission (2010), A decade of EU-funded GMO research (2001–2010), EUR 24473 (archived). https://web.archive.org/web/2016/http://ec.europa.eu/research/biosociety/pdf/a_decade_of_eu-funded_gmo_research.pdf

EU agencies and partnerships - EFSA (2008), PFOS, PFOA and their salts. https://doi.org/10.2903/j.efsa.2008.653 - EFSA Scientific Committee (3 Aug 2017), guidance on the weight of evidence approach. https://doi.org/10.2903/j.efsa.2017.4971 - EFSA Scientific Committee (24 Jan 2018), guidance on uncertainty analysis. https://doi.org/10.2903/j.efsa.2018.5123 - EFSA CONTAM (2018), PFOS and PFOA in food. https://doi.org/10.2903/j.efsa.2018.5194 - EFSA CONTAM (17 Sep 2020), PFAS in food. https://doi.org/10.2903/j.efsa.2020.6223 - EFSA CEP (19 Apr 2023), re-evaluation of BPA. https://doi.org/10.2903/j.efsa.2023.6857 - Eurostat, Environmental tax statistics (data extracted July 2026). https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Environmental_tax_statistics - PARC, Partnership for the Assessment of Risks from Chemicals (launched 11 May 2022). https://www.eu-parc.eu/ - EURION cluster (Horizon 2020). https://eurion-cluster.eu/ - NSC network (formerly the NanoSafety Cluster). https://nsc-community.eu/

US agencies, courts and executive actions - CDC, update of the blood lead reference value (28 Oct 2021). https://www.cdc.gov/lead-prevention/php/news-features/updates-blood-lead-reference-value.html - US EPA, Lead and Copper Rule Improvements (final 8 Oct 2024; page updated 29 Dec 2025). https://www.epa.gov/ground-water-and-drinking-water/lead-and-copper-rule-improvements - US EPA, final reconsideration of the PM NAAQS (7 Feb 2024; page updated 14 Apr 2026). https://www.epa.gov/pm-pollution/final-reconsideration-national-ambient-air-quality-standards-particulate-matter-pm - US EPA, news release, “EPA Launches Biggest Deregulatory Action in U.S. History” (12 Mar 2025). https://www.epa.gov/newsreleases/epa-launches-biggest-deregulatory-action-us-history - US EPA, PFAS National Primary Drinking Water Regulation (10 Apr 2024; page updated 18 May 2026). https://www.epa.gov/sdwa/and-polyfluoroalkyl-substances-pfas - US FDA, BPA use in food contact applications (content current as of 20 Apr 2023). https://www.fda.gov/food/food-packaging-other-substances-come-contact-food-information-consumers/bisphenol-bpa-use-food-contact-application - USDA ERS, MacDonald, Dong and Fuglie, Concentration and Competition in U.S. Agribusiness, EIB-256 (June 2023). https://www.ers.usda.gov/publications/pub-details?pubid=106794 ; summary PDF: https://www.ers.usda.gov/media/7666/eib-256-report-summary.pdf - US Court of Appeals for the Ninth Circuit, National Family Farm Coalition v. EPA, No. 19-70115 (3 Jun 2020). https://cdn.ca9.uscourts.gov/datastore/opinions/2020/06/03/19-70115.pdf - Executive Order 14300, “Ordering the Reform of the Nuclear Regulatory Commission” (23 May 2025). https://www.whitehouse.gov/presidential-actions/2025/05/ordering-the-reform-of-the-nuclear-regulatory-commission/ - US Surgeon General (2014), The Health Consequences of Smoking — 50 Years of Progress. https://www.ncbi.nlm.nih.gov/books/NBK179276/

WHO, IARC, UN and other national bodies - WHO, new global air quality guidelines (22 Sep 2021). https://www.who.int/news/item/22-09-2021-new-who-global-air-quality-guidelines-aim-to-save-millions-of-lives-from-air-pollution - WHO, aspartame hazard and risk assessment results (14 Jul 2023). https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released - IARC Monograph Vol. 107, PCBs and PBBs (2015). https://publications.iarc.who.int/131 - Lauby-Secretan et al., Lancet Oncol 14:287 (15 Mar 2013), PCB carcinogenicity. https://doi.org/10.1016/S1470-2045(13)70104-9 - Zahm et al., Lancet Oncol 25:16 (2024; online 30 Nov 2023), PFOA and PFOS carcinogenicity. https://doi.org/10.1016/S1470-2045(23)00622-8 - UN SEEA, Ecosystem Accounting (adopted March 2021). https://seea.un.org/ecosystem-accounting - CBD, Kunming-Montreal Global Biodiversity Framework, Target 14 (Dec 2022). https://www.cbd.int/gbf/targets/14 - Health Canada, titanium dioxide as a food additive (updated 6 Apr 2023). https://www.canada.ca/en/health-canada/services/food-nutrition/reports-publications/titanium-dioxide-food-additive-science-report.html - National Academies of Sciences, Engineering, and Medicine (2016), Genetically Engineered Crops: Experiences and Prospects. https://www.nationalacademies.org/publications/23395 ; summary: https://www.nationalacademies.org/read/23395/chapter/2 - Minamata Convention on Mercury (in force 16 Aug 2017). https://minamataconvention.org/en (not retrievable in this run)

Peer-reviewed literature - Ambec, Cohen, Elgie and Lanoie (2013), “The Porter Hypothesis at 20”, REEP 7(1):2–22. https://doi.org/10.1093/reep/res016 - Arp et al. (30 Oct 2024), “The Global Threat from the Irreversible Accumulation of Trifluoroacetic Acid (TFA)”, ES&T. https://doi.org/10.1021/acs.est.4c06189 - Bowman, Sylvester and Marino (2017), “Returning to the Patent Landscapes for Nanotechnology”, Methods Mol Biol. https://doi.org/10.1007/978-1-4939-6840-4_22 - Calel and Dechezleprêtre (2016), “Environmental Policy and Directed Technological Change”, REStat 98(1):173–191. https://doi.org/10.1162/REST_a_00470 - Castaño-Vinyals et al. (online 30 Dec 2021), MOBI-Kids, Environ Int. https://doi.org/10.1016/j.envint.2021.107069 - Cohen and Tubb (2018), “Meta-analysis of the Porter Hypothesis”, JAERE 5(2):371–399. https://doi.org/10.1086/695613 (abstract: https://ideas.repec.org/a/ucp/jaerec/doi10.1086-695613.html) - Cox (Oct 2007), “Regulatory False Positives: True, False, or Uncertain?”, Risk Analysis. https://doi.org/10.1111/j.1539-6924.2007.00975.x ; Hansen, Krayer von Krauss and Tickner, response (Oct 2007). https://doi.org/10.1111/j.1539-6924.2007.00970.x - Dechezleprêtre and Sato (Jul 2017), “The Impacts of Environmental Regulations on Competitiveness”, REEP 11(2):183–206. https://doi.org/10.1093/reep/rex013 - Garnett and Parsons (2017; online 18 May 2016), “Multi-Case Review of the Application of the Precautionary Principle in European Union Law and Case Law”, Risk Analysis 37(3). https://doi.org/10.1111/risa.12633 - Grandjean, Eriksen, Ellegaard and Wallin (10 Nov 2011), “The Matthew effect in environmental science publication”, Environ Health 10:96 (full text, PMC3229577). https://doi.org/10.1186/1476-069X-10-96 - Heindel et al. (2020), “Data integration, analysis, and interpretation of eight academic CLARITY-BPA studies”, Reprod Toxicol. https://doi.org/10.1016/j.reprotox.2020.05.014 - Karipidis et al. (30 Aug 2024), RF-EMF and cancer systematic review, Part I, Environ Int. https://doi.org/10.1016/j.envint.2024.108983 - Kortenkamp, Martin, Iacovidou and Scholze (2024; online 15 Nov 2023), “Drivers of divergent assessments of bisphenol-A hazards”, IJHEH. https://doi.org/10.1016/j.ijheh.2023.114293 - Lanphear et al. (12 Mar 2018), “Low-level lead exposure and mortality in US adults”, Lancet Public Health. https://doi.org/10.1016/S2468-2667(18)30025-2 - Larsen and Sánchez-Triana (12 Sep 2023), “Global health burden and cost of lead exposure”, Lancet Planet Health. https://doi.org/10.1016/S2542-5196(23)00166-3 - Löfstedt (Aug 2014), “The precautionary principle in the EU: Why a formal review is long overdue”, Risk Management 16:137–163. https://doi.org/10.1057/rm.2014.7 - Nielsen, Skjolding, Baun and Hansen (10 Oct 2023), “European nanomaterial legislation in the past 20 years”, NanoImpact. https://doi.org/10.1016/j.impact.2023.100487 - Pomar-Portillo et al. (2021), “Nanosafety research in Europe — Towards a focus on nano-enabled products”, NanoImpact. https://doi.org/10.1016/j.impact.2021.100323 - Richardson et al. (16 Aug 2023), INWORKS, BMJ. https://doi.org/10.1136/bmj-2022-074520 - Séralini et al., retraction notice, Food Chem Toxicol (announced 28 Nov 2013). https://doi.org/10.1016/j.fct.2013.11.047 ; republished study, Environ Sci Eur (24 Jun 2014). https://doi.org/10.1186/s12302-014-0014-5 - Smart, Blum and Wesseler (2017), “Trends in Approval Times for Genetically Engineered Crops in the United States and the European Union”, J Agric Econ. https://doi.org/10.1111/1477-9552.12171 - Steinberg et al. (12 Feb 2019), G-TwYST NK603 feeding studies, Arch Toxicol. https://doi.org/10.1007/s00204-019-02400-1 - Wesseler and Zilberman (2014), “The economic power of the Golden Rice opposition”, Environ Dev Econ. https://doi.org/10.1017/S1355770X1300065X - Zoeller et al. (Aug 2023), “European Medicines Agency Conflicts With EFSA on Bisphenol A Regulation”, J Endocr Soc. https://doi.org/10.1210/jendso/bvad107

Data queries (own analysis) - NCBI PubMed E-utilities (esearch, rettype=count), run 26 Sep 2026. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi. Title/abstract queries as listed in the Claim 7 table, each combined with AND YYYY[dp].

Secondary sources (used where primary sources could not be retrieved; flagged in text) - World Nuclear Association, Nuclear Power in Japan (updated 22 Sep 2026; industry association). https://world-nuclear.org/information-library/country-profiles/countries-g-n/japan-nuclear-power - Wikipedia, “Séralini affair” (retraction date and editor’s quotations). https://en.wikipedia.org/wiki/S%C3%A9ralini_affair - Wikipedia, “Paris Convention on Third Party Liability in the Field of Nuclear Energy” (entry into force of the 2004 Protocol). https://en.wikipedia.org/wiki/Paris_Convention_on_Third_Party_Liability_in_the_Field_of_Nuclear_Energy